Whereas CIC::DUX4 fusion is encountered in 95% of CIC-rearranged sarcomas of the soft tissue, the molecular spectrum of CNS cases seems to be larger with different fusion partners: CIC::LEUTX (29%) [38, 40, 48], CIC::NUTM1 (29%)[42, 45], CIC::DUX4 (18%) [37, 46, 47], ATXN1::DUX4 (12%) [43, 49], ATXN1::NUTM1 (6%) [44], and a frameshift deletion of the CIC gene (6%) [45]. The gene discussed is DUX4; the disease is sarcoma.